These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 7718318

  • 1. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
    Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, Braun HJ, Fett W, Fischer JT, Göbel B.
    Eur J Cancer; 1995; 31A(2):146-51. PubMed ID: 7718318
    [Abstract] [Full Text] [Related]

  • 2. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, Braun HJ, von Broen IM, Fischer JT, Gramatzki M.
    Onkologie; 1990 Dec; 13(6):458-60. PubMed ID: 2092283
    [Abstract] [Full Text] [Related]

  • 3. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D, Deicher H, Coldewey R, von Broen IM, Cammerer U, Hein R, Hoffmann L, Konyar H, Kreuser ED, Selbach J.
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [Abstract] [Full Text] [Related]

  • 4. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [Abstract] [Full Text] [Related]

  • 5. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
    Zervas K, Pouli A, Gregoraki B, Anagnostopoulos N, Dimopoulos MA, Bourantas K, Tzilianos M, Barbarousi D, Venetis E, Vyniou N, Maniatis A.
    Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP, Bergsagel D, Sicheri D, O'Reilly S, Wilson KS, Rubin S, Belch A, Shustik C, Barr R, Walker I.
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [Abstract] [Full Text] [Related]

  • 8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 9. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
    Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J.
    Br J Haematol; 1990 Feb 15; 74(2):185-91. PubMed ID: 2180471
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
    Bladé J, San Miguel JF, Escudero ML, Fontanillas M, Besalduch J, Gardella S, Arias J, García-Conde J, Carnero M, Marti JM, Rozman C, Estapé J, Montserrat E.
    Leukemia; 1998 Jul 15; 12(7):1144-8. PubMed ID: 9665202
    [Abstract] [Full Text] [Related]

  • 12. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.
    Montuoro A, De Rosa L, De Blasio A, Pacilli L, Petti N, De Laurenzi A.
    Br J Haematol; 1990 Nov 15; 76(3):365-8. PubMed ID: 2261347
    [Abstract] [Full Text] [Related]

  • 13. Current results of a multicenter trial in multiple myeloma.
    Peest D, Schmoll HJ, Schedel I, Deicher H, Boll J, Essers U, Gamm H, Glück S, Görg K, Gramatzki M.
    Onkologie; 1986 Jun 15; 9(3):168-9. PubMed ID: 3528964
    [Abstract] [Full Text] [Related]

  • 14. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
    Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J, Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA).
    Blood; 2005 Dec 01; 106(12):3755-9. PubMed ID: 16105975
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
    Dimopoulos MA, Weber D, Delasalle KB, Alexanian R.
    Cancer; 1993 Nov 01; 72(9):2589-92. PubMed ID: 8402480
    [Abstract] [Full Text] [Related]

  • 16. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.
    Osterborg A, Björkholm M, Björeman M, Brenning G, Carlson K, Celsing F, Gahrton G, Grimfors G, Gyllenhammar H, Hast R.
    Blood; 1993 Mar 15; 81(6):1428-34. PubMed ID: 8453092
    [Abstract] [Full Text] [Related]

  • 17. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
    Cohen AM, Meytes D, Many A, Brenner B, Aghai E, Shaklai M, Kaufman S, Shtalrid M, Attias D, Manor Y.
    Isr J Med Sci; 1995 Oct 15; 31(10):604-10. PubMed ID: 7591683
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
    Bladé J, San Miguel JF, Fontanillas M, Esteve J, Maldonado J, Alcalá A, Brunet S, García-Conde J, Besalduch J, Moro MJ, Fernández-Calvo J, Conde E, Font L, Gardella S, Carnero M, Carbonell F, Martí JM, Hernández-Martín J, Ortega F, Besses C, Ribera JM, Trujillo J, Escudero ML, Rozman C, Estapé J, Montserrat E.
    Hematol J; 2001 Oct 15; 2(4):272-8. PubMed ID: 11920260
    [Abstract] [Full Text] [Related]

  • 20. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
    Gola A, Usnarska-Zubkiewicz L, Wołowiec D, Urbaniak-Kujda D, Kotlarek-Haus S.
    Pol Arch Med Wewn; 1993 Aug 15; 90(2):134-41. PubMed ID: 8247946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.